124 related articles for article (PubMed ID: 38219387)
1. Liver-targeted nanoparticles delivering nitric oxide reduce portal hypertension in cirrhotic rats.
Perramón M; Navalón-López M; Fernández-Varo G; Moreno-Lanceta A; García-Pérez R; Faneca J; López-Moya M; Fornaguera C; García-Villoria J; Morales-Ruiz M; Melgar-Lesmes P; Borrós S; Jiménez W
Biomed Pharmacother; 2024 Feb; 171():116143. PubMed ID: 38219387
[TBL] [Abstract][Full Text] [Related]
2. Analysis of the nitric oxide-cyclic guanosine monophosphate pathway in experimental liver cirrhosis suggests phosphodiesterase-5 as potential target to treat portal hypertension.
Schaffner D; Lazaro A; Deibert P; Hasselblatt P; Stoll P; Fauth L; Baumstark MW; Merfort I; Schmitt-Graeff A; Kreisel W
World J Gastroenterol; 2018 Oct; 24(38):4356-4368. PubMed ID: 30344420
[TBL] [Abstract][Full Text] [Related]
3. Nitroflurbiprofen, a nitric oxide-releasing cyclooxygenase inhibitor, improves cirrhotic portal hypertension in rats.
Laleman W; Van Landeghem L; Van der Elst I; Zeegers M; Fevery J; Nevens F
Gastroenterology; 2007 Feb; 132(2):709-19. PubMed ID: 17258737
[TBL] [Abstract][Full Text] [Related]
4. Intraportal administration of glyceryl trinitrate or nitroprusside exerts more systemic than intrahepatic effects in anaesthetised cirrhotic rats.
Van de Casteele M; Hösli M; Sägesser H; Reichen J
J Hepatol; 1999 Aug; 31(2):300-5. PubMed ID: 10453944
[TBL] [Abstract][Full Text] [Related]
5. A liver-specific nitric oxide donor improves the intra-hepatic vascular response to both portal blood flow increase and methoxamine in cirrhotic rats.
Loureiro-Silva MR; Cadelina GW; Iwakiri Y; Groszmann RJ
J Hepatol; 2003 Dec; 39(6):940-6. PubMed ID: 14642609
[TBL] [Abstract][Full Text] [Related]
6. Tempol administration, a superoxide dismutase mimetic, reduces hepatic vascular resistance and portal pressure in cirrhotic rats.
García-Calderó H; Rodríguez-Vilarrupla A; Gracia-Sancho J; Diví M; Laviña B; Bosch J; García-Pagán JC
J Hepatol; 2011 Apr; 54(4):660-5. PubMed ID: 21159403
[TBL] [Abstract][Full Text] [Related]
7. The use of nanoparticles to deliver nitric oxide to hepatic stellate cells for treating liver fibrosis and portal hypertension.
Duong HT; Dong Z; Su L; Boyer C; George J; Davis TP; Wang J
Small; 2015 May; 11(19):2291-304. PubMed ID: 25641921
[TBL] [Abstract][Full Text] [Related]
8. Improvement of portal hypertension and hepatic blood flow in cirrhotic rats by oestrogen.
Sakamoto M; Ueno T; Nakamura T; Sakata R; Hasimoto O; Torimura T; Sata M
Eur J Clin Invest; 2005 Mar; 35(3):220-5. PubMed ID: 15733078
[TBL] [Abstract][Full Text] [Related]
9. Salviae miltiorrhizae ameliorates cirrhosis and portal hypertension by inhibiting nitric oxide in cirrhotic rats.
Wang H; Chen XP; Qiu FZ
Hepatobiliary Pancreat Dis Int; 2003 Aug; 2(3):391-6. PubMed ID: 14599946
[TBL] [Abstract][Full Text] [Related]
10. Cerium oxide nanoparticles reduce steatosis, portal hypertension and display anti-inflammatory properties in rats with liver fibrosis.
Oró D; Yudina T; Fernández-Varo G; Casals E; Reichenbach V; Casals G; González de la Presa B; Sandalinas S; Carvajal S; Puntes V; Jiménez W
J Hepatol; 2016 Mar; 64(3):691-8. PubMed ID: 26519601
[TBL] [Abstract][Full Text] [Related]
11. Current concepts on the role of nitric oxide in portal hypertension.
Hu LS; George J; Wang JH
World J Gastroenterol; 2013 Mar; 19(11):1707-17. PubMed ID: 23555159
[TBL] [Abstract][Full Text] [Related]
12. AMPK agonist AICAR ameliorates portal hypertension and liver cirrhosis via NO pathway in the BDL rat model.
Hu L; Su L; Dong Z; Wu Y; Lv Y; George J; Wang J
J Mol Med (Berl); 2019 Mar; 97(3):423-434. PubMed ID: 30721324
[TBL] [Abstract][Full Text] [Related]
13. NCX-1000, a nitric oxide-releasing derivative of ursodeoxycholic acid, ameliorates portal hypertension and lowers norepinephrine-induced intrahepatic resistance in the isolated and perfused rat liver.
Fiorucci S; Antonelli E; Brancaleone V; Sanpaolo L; Orlandi S; Distrutti E; Acuto G; Clerici C; Baldoni M; Del Soldato P; Morelli A
J Hepatol; 2003 Dec; 39(6):932-9. PubMed ID: 14642608
[TBL] [Abstract][Full Text] [Related]
14. Role of estrogen receptor β selective agonist in ameliorating portal hypertension in rats with CCl4-induced liver cirrhosis.
Zhang CG; Zhang B; Deng WS; Duan M; Chen W; Wu ZY
World J Gastroenterol; 2016 May; 22(18):4484-500. PubMed ID: 27182159
[TBL] [Abstract][Full Text] [Related]
15. Tetrandrine ameliorates cirrhosis and portal hypertension by inhibiting nitric oxide in cirrhotic rats.
Wang H; Chen X
J Huazhong Univ Sci Technolog Med Sci; 2004; 24(4):385-8, 395. PubMed ID: 15587405
[TBL] [Abstract][Full Text] [Related]
16. Superoxide dismutase gene transfer reduces portal pressure in CCl4 cirrhotic rats with portal hypertension.
Laviña B; Gracia-Sancho J; Rodríguez-Vilarrupla A; Chu Y; Heistad DD; Bosch J; García-Pagán JC
Gut; 2009 Jan; 58(1):118-25. PubMed ID: 18829979
[TBL] [Abstract][Full Text] [Related]
17. Mitochondria-targeted antioxidant mitoquinone deactivates human and rat hepatic stellate cells and reduces portal hypertension in cirrhotic rats.
Vilaseca M; García-Calderó H; Lafoz E; Ruart M; López-Sanjurjo CI; Murphy MP; Deulofeu R; Bosch J; Hernández-Gea V; Gracia-Sancho J; García-Pagán JC
Liver Int; 2017 Jul; 37(7):1002-1012. PubMed ID: 28371136
[TBL] [Abstract][Full Text] [Related]
18. Asymmetric dimethylarginine (ADMA) determines the improvement of hepatic endothelial dysfunction by vitamin E in cirrhotic rats.
Yang YY; Lee TY; Huang YT; Chan CC; Yeh YC; Lee FY; Lee SD; Lin HC
Liver Int; 2012 Jan; 32(1):48-57. PubMed ID: 22098317
[TBL] [Abstract][Full Text] [Related]
19. Treatment of portal hypertension with NCX-1000, a liver-specific NO donor. A review of its current status.
Fiorucci S; Antonelli E; Tocchetti P; Morelli A
Cardiovasc Drug Rev; 2004; 22(2):135-46. PubMed ID: 15179450
[TBL] [Abstract][Full Text] [Related]
20. Comparison of vascular nitric oxide production and systemic hemodynamics in cirrhosis versus prehepatic portal hypertension in rats.
Niederberger M; Ginés P; Martin PY; Tsai P; Morris K; McMurtry I; Schrier RW
Hepatology; 1996 Oct; 24(4):947-51. PubMed ID: 8855203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
